Project Grant F32HL178024
Award Date
6/30/25
Completion Date
12/31/27
Dollars Obligated
$154K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,869,326 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB). The funding supports a 4-year research project to identify novel strategies to mitigate cardiac damage and dysfunction following invasive pneumococcal disease. The project aims to test the hypothesis that the S100A8/9-NLRP3-IL-1β signaling circuit and excessive recruitment of proinflammatory...
This $2,037,758 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of mitochondrial calcium uptake in regulating lung epithelial regeneration following bacterial pneumonia. The project aims to elucidate how mitochondrial calcium signaling and metabolic pathways, specifically the succinate/α-ketoglutarate ratio, impact epigenetic regulation and the differentiation...
The federal Project Grant award R01HL169973, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), is supporting research on how the immune system's antiviral response to respiratory viral infections, such as respiratory syncytial virus (RSV), can promote the growth of Pseudomonas aeruginosa biofilms in cystic fibrosis patients. This $674,449 award, effective September 1, 2024 through June 30, 2028, aims to elucidate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $124,536 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the protective role of B cells in hyperoxic lung injury. The research aims to characterize the dynamics of B cell responses during hyperoxia and examine the protective impacts of B cell supplementation, as well as...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $600,761 to the Regents of the University of Michigan to investigate the mechanisms by which early-life exposure to inflammatory triggers, such as bacterial lipopolysaccharide or hyperoxia, induce the expression of activating receptor ligands on lung cells and activate NKG2D+...
This $755,228.26 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the mechanisms by which the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) modulates inflammation and promotes resolution during pneumonia. The research aims to uncover how LOX-1 signaling in leukocytes, particularly alveolar macrophages and recruited neutrophils, mediates protective...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $610,236 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation (Massachusetts General Hospital) to study the use of B cells for treating acute respiratory distress syndrome (ARDS) and associated neurological complications. The project aims to investigate the protective effects of adoptively transferred naive B cells...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $392,660 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania. The 4-year grant, which runs from May 1, 2025 to January 31, 2029, supports research to investigate the role of red blood cells and the Toll-like Receptor 7 (TLR7) in regulating the immune response during sepsis. The project aims to elucidate novel mechanisms of immune dysregulation in sepsis...
The University of Pittsburgh was awarded a $607,952 Project Grant under the National Heart, Lung, and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) to study indole metabolites as novel danger signals contributing to acute lung injury and acute respiratory distress syndrome (ARDS). The grant, running from September 16, 2024 to August 31, 2025, will support research to determine the mechanisms by which microbe-derived indole metabolites induce cell death and...
This federal Project Grant award of $915,924 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research focused on understanding how disruptions to early-life gut microbiome colonization can impair the development and function of key lung immune and epithelial cells. The research aims to elucidate how these microbiome-driven changes contribute to increased susceptibility to respiratory infections and the...